Clinical Benefit of Post–Trastuzumab Deruxtecan Treatment in Patients With HER2+ Unresectable or Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study
Breast Cancer Res Treat 2024 May 26;[EPub Ahead of Print], A Isogai, K Nozawa, A Nakakami, R Komaki, Y Ozaki, Y Endo, A Kataoka, H Kotani, A Yoshimura, M Hattori, M Sawaki, H IwataFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.